domenica, 24 ottobre 2021
Medinews
26 Aprile 2017

FDA Grants Atezolizumab Accelerated Approval as Initial Treatment for Some Advanced Bladder Cancers

April 18, 2017 – On April 17, the U.S. Food and Drug Administration (FDA) granted accelerated approval to atezolizumab for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy. Atezolizumab was previously approved for people with locally advanced or metastatic urothelial carcinoma who have disease progression during or following any platinum-containing chemotherapy, or within 12 … (leggi tutto)

TORNA INDIETRO